Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mCapOX vs mFOLFOX6 with Cetuximab in Left-Sided mCRC
NCT06616259Phase 3Not yet recruiting
- Start
- Sep 2024
- Primary completion
- Sep 2028
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of capecitabine in colorectal cancer (CRC) (2 arms). Primary endpoint: Progression Free Survival at 3 years. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
capecitabine
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT06616259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06616259.